Berkeley Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Berkeley Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,752	Closed	-$308K	–	162
2021 Q4	$308K	Sell	2,752 -22	-0.8%	-$2.65K	0.13%	109
2021 Q3	$349K	Sell	2,774 -12	-0.4%	-$1.54K	0.16%	91
2021 Q2	$377K	Sell	2,786 -77	-3%	-$10.1K	0.17%	86
2021 Q1	$388K	Buy	2,863 +13	+0.5%	+$1.95K	0.19%	78
2020 Q4	$401K	Sell	2,850 -151	-5%	-$19.3K	0.21%	72
2020 Q3	$334K	Buy	3,001 +108	+4%	+$12.1K	0.2%	71
2020 Q2	$324K	Buy	+2,893	New	+$285K	0.2%	78
2020 Q1	–	Sell	-2,918	Closed	-$278K	–	139
2019 Q4	$278K	Buy	+2,918	New	+$252K	0.14%	114
2019 Q3	–	Sell	-3,032	Closed	-$266K	–	135
2019 Q2	$266K	Buy	3,032 +92	+3%	+$7.85K	0.12%	120
2019 Q1	$266K	Buy	+2,940	New	+$250K	0.13%	117
2018 Q3	–	Sell	-2,678	Closed	-$254K	–	123
2018 Q2	$254K	Buy	+2,678	New	+$246K	0.15%	108
2016 Q1	–	Sell	-4,308	Closed	-$302K	–	124
2015 Q4	$302K	Buy	+4,308	New	+$294K	0.25%	79

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Berkeley Capital Partners's XBI Position: Q1 2022 in Review

Berkeley Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 2,752 shares — an estimated $308K sold.

Berkeley Capital Partners first reported a position in XBI in Q4 2015 and held it in 12 quarters. The position peaked at $401K in Q4 2020. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Berkeley Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Berkeley Capital Partners sold 2,752 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $308K.
Berkeley Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 12 quarters.
Berkeley Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $401K in Q4 2020.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Berkeley Capital Partners's 13F filing for Q1 2022, filed 5 May 2022.